JAZZ Stock Recent News

Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.

Jazz Pharmaceuticals plc. (NASDAQ:JAZZ ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Andrea Flynn - Vice President and Head-Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renée Galá - President and Chief Operating Officer Rob Iannone - Executive Vice President and Global Head-R&D Phil Johnson - Executive Vice President and Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Marc Goodman - Leerink Jessica Fye - JPMorgan Annabel Samimy - Stifel.

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.30 per share, beating the Zacks Consensus Estimate of $4.68 per share. This compares to earnings of $4.51 per share a year ago.

– 15% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 10% year-over-year –– Zanidatamab granted Priority Review by U.S. FDA for 2L BTC; PDUFA date of November 29, 2024 –– Near-term, late-stage pipeline catalysts anticipated through 2025 –– Narrowing 2024 total revenue guidance to $4.0 to $4.1 billion –– Affirming GAAP and non-GAAP adjusted net income guidance – DUBLIN , July 31, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2024 and updated guidance for 2024. "Jazz's record revenues of over $1 billion in the second quarter were driven by strong execution and increased demand for our key growth drivers, Xywav, Epidiolex and Rylaze.

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DUBLIN , July 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that it has completed a repricing of the approximately $2.7 billion outstanding balance of its U.S. dollar term loans under its credit facility. The applicable margin above Term SOFR will be reduced by 75 basis points (from 300 basis points to 225 basis points) and the credit spread adjustment will be removed, resulting in anticipated interest savings of approximately $23 million on an annualized basis.

DUBLIN , July 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

Investors need to pay close attention to JAZZ Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.

Ms. Pearce brings over 30 years of commercial experience and track record of success across global markets DUBLIN , July 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Samantha Pearce, Senior Vice President (SVP), Europe and International, has been promoted to Chief Commercial Officer (CCO) effective August 1, 2024. Ms. Pearce joined Jazz as SVP, Europe and International, in 2020, and brings more than 30 years of commercial experience in the pharmaceutical industry.

With the federal government taking steps to reschedule cannabis to Schedule III, effectively creating a form of medical cannabis legalization, the future of  cannabis stocks is under intense scrutiny. While cannabis stocks initially surged on the news, they quickly settled back to their previous levels.